Senior Director, Payor and Health Systems Liaison, East

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 7, 2026

Salary

$264K-$290K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$61,842 U.S. median for this role

Projected growth (BLS Employment Projections)

+1.9% - Slower

348% above the BLS role benchmark for operations aggregate.

Posted salary is far from this role benchmark; treat it as low confidence.

Matched to SOC 11-1021 - Operations aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Operations From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Work mode

Remote From the posting source checked Jun 20, 2026

In-office days

0 days From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Late-stage From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Senior Director, Payor and Health Systems Liaison, East Remote (United States) Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company's R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company's RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway. The Opportunity: Reporting to the Executive Director of Field Medical Affairs, the Payor and Health Systems Liaison will own and shape the scientific payer/access strategy for the US region. They will develop and cultivate relationships with key decision-makers and other influencers in managed care organizations, government programs, employers, hospital systems and product distribution companies, to support appropriate patient access and evidence-based utilization for Revolution Medicine's products. A key aspect of the Payor and Health Systems Liaison responsibilities is to keep payers and other key external constituents or influencers abreast of new product launches, line extensions and Medical Affairs research. The Payor and Health Systems Liaison leads high‑impact clinical, scientific, and population health engagement with external access stakeholders, including Payers, Group Purchasing Organizations (GPOs), Community Aggregators, and Integrated Delivery Networks (IDNs), while ensuring strong integration between Medical Affairs, HEOR, and Market Access strategy. Responsibilities

Read the full description at www.revmed.com. FewerJobs shows a preview and links to the original posting.